Boston Scientific Corporation (BSX) PT Set at $26.00 by Oppenheimer Holdings, Inc., Report finds

Boston Scientific Corporation (BSX) PT Set at $26.00 by Oppenheimer Holdings, Inc., Report finds

Oppenheimer Holdings, Inc. set a $26.00 price objective on Boston Scientific Corporation (NYSE:BSX) in a research note published on Friday morning. The brokerage currently has a hold rating on the stock.

Several other analysts have also recently weighed in on the stock. Jefferies Group LLC reaffirmed a hold rating and issued a $26.00 target price on shares of Boston Scientific Corporation in a report on Friday, February 3rd. Needham & Company LLC raised their target price on shares of Boston Scientific Corporation from $28.00 to $29.00 and gave the company a buy rating in a report on Thursday, February 2nd. TheStreet raised shares of Boston Scientific Corporation from a c+ rating to a b rating in a report on Tuesday, January 17th. BTIG Research reissued a neutral rating on shares of Boston Scientific Corporation in a report on Sunday, January 8th. Finally, Vetr raised shares of Boston Scientific Corporation from a buy rating to a strong-buy rating and set a $23.52 price objective on the stock in a report on Monday, December 5th. Six investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. Boston Scientific Corporation has an average rating of Buy and a consensus price target of $25.88.

Shares of Boston Scientific Corporation (NYSE:BSX) opened at 25.24 on Friday. The stock has a 50 day moving average of $23.27 and a 200 day moving average of $22.91. The stock has a market capitalization of $34.38 billion, a P/E ratio of 100.96 and a beta of 1.06. Boston Scientific Corporation has a 12-month low of $16.40 and a 12-month high of $25.38.

Boston Scientific Corporation (NYSE:BSX) last issued its earnings results on Thursday, February 2nd. The company reported $0.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.01. The firm had revenue of $2.19 billion for the quarter, compared to analysts’ expectations of $2.16 billion. Boston Scientific Corporation had a net margin of 4.14% and a return on equity of 23.70%. The firm’s revenue was up 10.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.26 earnings per share. Equities research analysts anticipate that Boston Scientific Corporation will post $1.25 EPS for the current fiscal year.

In related news, EVP Timothy A. Pratt sold 6,195 shares of the business’s stock in a transaction dated Monday, January 9th. The shares were sold at an average price of $22.24, for a total value of $137,776.80. Following the completion of the transaction, the executive vice president now owns 231,273 shares of the company’s stock, valued at approximately $5,143,511.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy A. Pratt sold 26,726 shares of the business’s stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $20.48, for a total transaction of $547,348.48. Following the completion of the transaction, the executive vice president now directly owns 260,430 shares of the company’s stock, valued at approximately $5,333,606.40. The disclosure for this sale can be found here. Insiders sold a total of 123,936 shares of company stock valued at $2,949,224 in the last three months. 1.31% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Armor Investment Advisors LLC purchased a new position in shares of Boston Scientific Corporation during the fourth quarter valued at $270,000. Meiji Yasuda Asset Management Co Ltd. boosted its stake in Boston Scientific Corporation by 192.9% in the fourth quarter. Meiji Yasuda Asset Management Co Ltd. now owns 51,281 shares of the company’s stock valued at $1,109,000 after buying an additional 33,770 shares during the period. Comerica Bank boosted its stake in Boston Scientific Corporation by 2.7% in the fourth quarter. Comerica Bank now owns 357,544 shares of the company’s stock valued at $8,517,000 after buying an additional 9,391 shares during the period. Commerzbank Aktiengesellschaft FI boosted its stake in Boston Scientific Corporation by 33.8% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 22,567 shares of the company’s stock valued at $488,000 after buying an additional 5,700 shares during the period. Finally, ING Groep NV acquired a new stake in Boston Scientific Corporation during the fourth quarter valued at approximately $2,465,000. 90.97% of the stock is owned by hedge funds and other institutional investors.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.

Related posts

Leave a Comment

Boston Scientific Corporation (BSX) PT Set at $26.00 by Oppenheimer Holdings, Inc.

Boston Scientific Corporation (BSX) PT Set at $26.00 by Oppenheimer Holdings, Inc.

Oppenheimer Holdings, Inc. set a $26.00 price objective on Boston Scientific Corporation (NYSE:BSX) in a research note published on Friday morning. The brokerage currently has a hold rating on the stock.

Several other analysts have also recently weighed in on the stock. Jefferies Group LLC reaffirmed a hold rating and issued a $26.00 target price on shares of Boston Scientific Corporation in a report on Friday, February 3rd. Needham & Company LLC raised their target price on shares of Boston Scientific Corporation from $28.00 to $29.00 and gave the company a buy rating in a report on Thursday, February 2nd. TheStreet raised shares of Boston Scientific Corporation from a c+ rating to a b rating in a report on Tuesday, January 17th. BTIG Research reissued a neutral rating on shares of Boston Scientific Corporation in a report on Sunday, January 8th. Finally, Vetr raised shares of Boston Scientific Corporation from a buy rating to a strong-buy rating and set a $23.52 price objective on the stock in a report on Monday, December 5th. Six investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. Boston Scientific Corporation has an average rating of Buy and a consensus price target of $25.88.

Shares of Boston Scientific Corporation (NYSE:BSX) opened at 25.24 on Friday. The stock has a 50 day moving average of $23.27 and a 200 day moving average of $22.91. The stock has a market capitalization of $34.38 billion, a P/E ratio of 100.96 and a beta of 1.06. Boston Scientific Corporation has a 12-month low of $16.40 and a 12-month high of $25.38.

Boston Scientific Corporation (NYSE:BSX) last issued its earnings results on Thursday, February 2nd. The company reported $0.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.01. The firm had revenue of $2.19 billion for the quarter, compared to analysts’ expectations of $2.16 billion. Boston Scientific Corporation had a net margin of 4.14% and a return on equity of 23.70%. The firm’s revenue was up 10.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.26 earnings per share. Equities research analysts anticipate that Boston Scientific Corporation will post $1.25 EPS for the current fiscal year.

In related news, EVP Timothy A. Pratt sold 6,195 shares of the business’s stock in a transaction dated Monday, January 9th. The shares were sold at an average price of $22.24, for a total value of $137,776.80. Following the completion of the transaction, the executive vice president now owns 231,273 shares of the company’s stock, valued at approximately $5,143,511.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy A. Pratt sold 26,726 shares of the business’s stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $20.48, for a total transaction of $547,348.48. Following the completion of the transaction, the executive vice president now directly owns 260,430 shares of the company’s stock, valued at approximately $5,333,606.40. The disclosure for this sale can be found here. Insiders sold a total of 123,936 shares of company stock valued at $2,949,224 in the last three months. 1.31% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Armor Investment Advisors LLC purchased a new position in shares of Boston Scientific Corporation during the fourth quarter valued at $270,000. Meiji Yasuda Asset Management Co Ltd. boosted its stake in Boston Scientific Corporation by 192.9% in the fourth quarter. Meiji Yasuda Asset Management Co Ltd. now owns 51,281 shares of the company’s stock valued at $1,109,000 after buying an additional 33,770 shares during the period. Comerica Bank boosted its stake in Boston Scientific Corporation by 2.7% in the fourth quarter. Comerica Bank now owns 357,544 shares of the company’s stock valued at $8,517,000 after buying an additional 9,391 shares during the period. Commerzbank Aktiengesellschaft FI boosted its stake in Boston Scientific Corporation by 33.8% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 22,567 shares of the company’s stock valued at $488,000 after buying an additional 5,700 shares during the period. Finally, ING Groep NV acquired a new stake in Boston Scientific Corporation during the fourth quarter valued at approximately $2,465,000. 90.97% of the stock is owned by hedge funds and other institutional investors.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.

Related posts

Leave a Comment